Order Article Reprints

Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, Borea R, Raffa S, Damassi A, Ponzano M, et al. The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. Cancers. 2020; 12(11):3213. https://doi.org/10.3390/cancers12113213

Bauckneht, Matteo, Sara Elena Rebuzzi, Alessio Signori, Maria Isabella Donegani, Veronica Murianni, Alberto Miceli, Roberto Borea, Stefano Raffa, Alessandra Damassi, Marta Ponzano, and et al. 2020. "The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study" Cancers 12, no. 11: 3213. https://doi.org/10.3390/cancers12113213

Bauckneht, M., Rebuzzi, S. E., Signori, A., Donegani, M. I., Murianni, V., Miceli, A., Borea, R., Raffa, S., Damassi, A., Ponzano, M., Catalano, F., Martelli, V., Marini, C., Boccardo, F., Morbelli, S., Sambuceti, G., & Fornarini, G. (2020). The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. Cancers, 12(11), 3213. https://doi.org/10.3390/cancers12113213